Stock BIOSANTE PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News BioSante Pharmaceuticals, Inc. Nasdaq

Equities

US09065V2034

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for BioSante Pharmaceuticals, Inc.
Jun. 06 Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing MT
Jun. 05 ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ani Pharmaceuticals Insider Sold Shares Worth $317,900, According to a Recent SEC Filing
MT
ANI Pharmaceuticals Insider Sold Shares Worth $1,288,200, According to a Recent SEC Filing
MT
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference
AQ
Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing
MT
Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
PR
ANI Pharmaceuticals Launches Kionex Suspension
MT
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
AQ
ANI Pharmaceuticals, Inc. Announces the Launch of Kionex Suspension
CI
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing
MT
ANI PHARMACEUTICALS REPORTS RECORD FIRST QUARTER 2024 FINANCIAL RESULTS AND REITERATES 2024 GUIDANCE
AQ
ANI Pharmaceuticals Seeks M&A
CI
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024
CI
Transcript : ANI Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 10, 2024
ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance
MT
Futures Rebound Pre-Bell Ahead of Earnings, Next Week's Inflation Reports; Asia, Europe Gain
MT
ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 Revenue Range $520M - $542M
MT
(ANIP) ANI PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $4.26 - $4.67
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Reports Q1 Revenue $137.4M, vs. Street Est of $126M
MT
Earnings Flash (ANIP) ANI PHARMACEUTICALS Posts Q1 EPS $1.21, vs. Street Est of $1.00
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANIP Stock
  4. Stock
  5. News BioSante Pharmaceuticals, Inc.